Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.

Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, Galosi AB, Scarpelli M, Montironi R.

Front Oncol. 2018 Dec 21;8:653. doi: 10.3389/fonc.2018.00653. eCollection 2018. Review.

2.

Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.

Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, Montironi R.

J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):555-63. Review.

PMID:
25620167
3.

The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Ristau BT, O'Keefe DS, Bacich DJ.

Urol Oncol. 2014 Apr;32(3):272-9. doi: 10.1016/j.urolonc.2013.09.003. Epub 2013 Dec 8. Review.

4.

Quenched indocyanine green-anti-prostate-specific membrane antigen antibody J591.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Dec 8 [updated 2012 Mar 1].

5.

Thermally cross-linked superparamagnetic iron oxide nanoparticle-A10 RNA aptamer-doxorubicin conjugate.

Zhang H.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Aug 29 [updated 2008 Oct 8].

6.

Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.

Wüstemann T, Bauder-Wüst U, Schäfer M, Eder M, Benesova M, Leotta K, Kratochwil C, Haberkorn U, Kopka K, Mier W.

Theranostics. 2016 Apr 28;6(8):1085-95. doi: 10.7150/thno.13448. eCollection 2016.

7.

123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedoic acid.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Sep 29 [updated 2009 Nov 24].

8.

123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido)pentyl)ureido)pentanedoic acid.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Sep 29 [updated 2009 Nov 24].

9.

PSMA PET and Radionuclide Therapy in Prostate Cancer.

Bouchelouche K, Turkbey B, Choyke PL.

Semin Nucl Med. 2016 Nov;46(6):522-535. doi: 10.1053/j.semnuclmed.2016.07.006. Epub 2016 Sep 3. Review.

10.

PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30. doi: 10.1038/pcan.2016.13. Epub 2016 May 3. Review.

11.

PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Mease RC, Foss CA, Pomper MG.

Curr Top Med Chem. 2013;13(8):951-62. Review.

12.

Quantum dot-A10 RNA aptamer-doxorubicin conjugate .

Zhang H.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Aug 25 [updated 2008 Oct 8].

13.

89Zr-Desferrioxamine B-7E11 anti-prostate-specific membrane antigen monoclonal antibody.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Nov 22 [updated 2012 Feb 23].

14.

Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.

Hofman MS, Hicks RJ, Maurer T, Eiber M.

Radiographics. 2018 Jan-Feb;38(1):200-217. doi: 10.1148/rg.2018170108. Review.

PMID:
29320333
15.

Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.

Pillai MRA, Nanabala R, Joy A, Sasikumar A, Russ Knapp FF.

Nucl Med Biol. 2016 Nov;43(11):692-720. doi: 10.1016/j.nucmedbio.2016.08.006. Epub 2016 Aug 11. Review.

PMID:
27589333
16.

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.

Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC.

Theranostics. 2015 Oct 18;5(12):1388-401. doi: 10.7150/thno.13348. eCollection 2015. Review.

17.

Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.

Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL.

Semin Nucl Med. 2016 Sep;46(5):405-18. doi: 10.1053/j.semnuclmed.2016.04.004. Review.

PMID:
27553466
18.

Quantum dot 800–prostate-specific membrane antigen antibody J591.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Feb 28 [updated 2011 May 18].

19.

New aspects of molecular imaging in prostate cancer.

Ceci F, Castellucci P, Cerci JJ, Fanti S.

Methods. 2017 Nov 1;130:36-41. doi: 10.1016/j.ymeth.2017.07.009. Epub 2017 Jul 13. Review.

PMID:
28711565
20.

Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.

Bouchelouche K, Choyke PL.

Curr Opin Oncol. 2016 May;28(3):216-21. doi: 10.1097/CCO.0000000000000277. Review.

Supplemental Content

Support Center